CalendarFinancials941 views7 min read

Field Trip Health & Wellness Ltd. Strengthens Leadership Team With Two Executive Appointments, Schedules Fiscal Second Quarter 2023 Conference Call

Field Trip HealthNovember 22, 2022

Appoints Stacey Hoisak as Senior Vice President, General Counsel, and Dr. Monique Moller as Vice President, Integrative HealthSchedules Fiscal Second Quarter 2023 Conference Call for Tuesday, November 29, 2022, at 8:30 AM ET TORONTO, Nov. 22, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), a glo... Read More...

Calendar683 views3 min read

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022

Numinus WellnessNovember 22, 2022

VANCOUVER, BC, Nov. 22, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Thursday, Dece... Read More...

738 views4 min read

Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement

Mydecine Innovations GroupNovember 21, 2022

DENVER, Nov. 21, 2022 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in con... Read More...

1080 views3 min read

Pure Extracts Receives Approval from Manitoba Liquor & Lotteries to list Pure Pulls Vapes and Pure Chews Edibles

Pure Extracts TechnologiesNovember 16, 2022

VANCOUVER, British Columbia, Nov. 16, 2022 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and functional mushrooms, is pleased to announce that its wholly-owned subsidiary, Pure Extracts Manufacturing Corp., has rece... Read More...

896 views5 min read

Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

CybinNovember 16, 2022

TORONTO, November 15, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 20... Read More...

Financials1282 views16 min read

Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022

Mydecine Innovations GroupNovember 14, 2022

DENVER, Nov. 14, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported company highlights and financial results for the nine months ended September 30, 2022. Company Highlights In 2022, Mydecin... Read More...

116 views2 min read

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

Silo PharmaNovember 11, 2022

ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine. The ob... Read More...

Capital Raise121 views4 min read

Psyence Group Announces Strategic Private Placement

Psyence GroupNovember 10, 2022

TORONTO, Nov. 10, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has received subscription agreements for gross proceeds of CAD$1.22 million from a consortium ... Read More...

52 views2 min read

Miami on November 3-5, 2022

Numinus WellnessOctober 31, 2022

 VANCOUVER, BC, Oct. 31, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Wonderland: Miami hosted by Microdose to be held at the Mana Wynwood Convention Cent... Read More...

40 views5 min read

Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness

Numinus WellnessOctober 28, 2022

Clinical program broadens access to ketamine-assisted therapy for an underserved population VANCOUVER, BC, Oct. 28, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the launch of its Ket... Read More...

33 views9 min read

HAVN Life Announces Retail Listing With Loblaws Company Ltd.

HAVN Life SciencesOctober 27, 2022

The Company's line of plant and mushroom-based natural health products will be available at LCL grocery banners across CanadaVANCOUVER, BC, Oct. 27, 2022 - HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the d... Read More...

36 views6 min read

Delic Labs President and CSO Dr. Markus Roggen to Discuss the Importance of R&D for Business Growth at MJBizCon

Delic HoldingsOctober 27, 2022

Dr. Markus Roggen, President and Chief Science Officer for Delic Labs, will participate in a panel discussion about building scientific trust and using research and development to differentiate a brand and maximize revenuesVANCOUVER, BC, Oct. 27, 2022 - Delic Holdings Corp ("Delic") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new m... Read More...

CalendarFinancials114 views3 min read

COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022

COMPASS Pathways plcOctober 27, 2022

COMPASS PathwaysLONDON, Oct. 26, 2022 -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2022, and provide an update on recent business developments on 3 Nov... Read More...

372 views4 min read

Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference

Silo PharmaOctober 27, 2022

Silo Pharma, Inc.ENGLEWOOD CLIFFS, NJ, Oct. 26, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that James Kuo, M.D. M.B.A, Vice President of R&D, will speak as a panelist at Wonderland: Miam... Read More...

30 views2 min read

Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study

Silo PharmaOctober 20, 2022

ENGLEWOOD CLIFFS, NJ, Oct. 20, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD), as... Read More...

1109 views2 min read

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics

Silo PharmaOctober 18, 2022

ENGLEWOOD CLIFFS, NJ, Oct. 18, 2022 -- Silo Pharma, Inc. (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced it has entered into an agreement with Columbia University pursuant to which Silo has been granted an extension for i... Read More...

860 views4 min read

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive TherapeuticsOctober 14, 2022

TORONTO, Oct. 14, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has finalized an amended protocol to the U.S. Food & Drug Admi... Read More...

1031 views4 min read

Lobe Sciences Announces the Completion of cGMP Production of Clinical Supplies For Upcoming Clinical Trials

Lobe SciencesOctober 14, 2022

Appointment of Philip J. Young, CEO, as Board ChairmanVancouver, British Columbia--(Newsfile Corp. - October 13, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it... Read More...

129 views7 min read

Optimi Health Announces Closing of Strategic Non-Brokered Private Placement

Optimi HealthOctober 12, 2022

Optimi Health Corp.Chip Wilson expands current share position and commits gross proceeds of up to $3.27 millionNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS.Highlights:$1.85 million in proceeds receive... Read More...

239 views2 min read

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Silo PharmaOctober 10, 2022

Studies of SP-26, the company’s proprietary, time-released ketamine show positive results in reducing neuropathic nerve pain  ENGLEWOOD CLIFFS, NJ, Oct. 10, 2022 --  Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, toda... Read More...

Calendar999 views3 min read

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022

Numinus WellnessOctober 7, 2022

VANCOUVER, BC, Oct. 7, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a Water Tower Research Fireside Chat on Thur... Read More...

149 views6 min read

Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health

Optimi HealthOctober 6, 2022

Highlights: The safe supply of psychedelic drug products manufactured at a GMP-level is critical in treating serious mental health issues. Minister of Mental Health and Addictions, the Honourable Carolyn Bennett, has publicly stated that safe drug supply is paramount to reducing overdose deaths.Optimi Health is the largest cultivator of n... Read More...

1122 views2 min read

Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12

Silo PharmaOctober 6, 2022

Presentation to feature Company’s novel therapeutic candidates under development in collaboration with leading academic institutions ENGLEWOOD CLIFFS, NJ, Oct. 06, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research,... Read More...

157 views4 min read

Lobe Sciences Announces the Appointment of Baxter F. Phillips III to Its Board of Directors

Lobe SciencesOctober 5, 2022

Vancouver, British Columbia--(Newsfile Corp. - October 5, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that Baxter F. Phillips III has been appointed to the Board of... Read More...

1314 views3 min read

Pure Extracts Receives Purchase Order for a New Listing of Cured Resin Vape Carts from the Ontario Cannabis Store

Pure Extracts TechnologiesOctober 5, 2022

VANCOUVER, British Columbia, Oct. 05, 2022 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and functional mushrooms, is pleased to announce that its wholly-owned subsidiary, Pure Extracts Manufacturing Corp., has rece... Read More...

193 views4 min read

Numinus Develops Mushroom Tea for Use in Psychedelic Research

Numinus WellnessOctober 5, 2022

Psilocybin-containing tea bag offers substitute for whole mushrooms and other solid therapeutics VANCOUVER, B.C, Oct. 5, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its researc... Read More...

Calendar896 views4 min read

Field Trip Health & Wellness to Participate in the Cantor Fitzgerald Symposium on Mental Health Clinics on October 11th

Field Trip HealthOctober 4, 2022

TORONTO, Oct. 04, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), a global leader in psychedelic therapies, today announced it will participate in a virtual fireside chat at Cantor Fitzgerald’s “Symposium on Mental Health Clinics,” taking place on Tuesday, October 11, 2022. Mujeeb Jafferi, Presi... Read More...

1460 views2 min read

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

Silo PharmaOctober 3, 2022

Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine ENGLEWOOD CLIFFS, NJ, Oct. 03, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it is working ... Read More...

Capital Raise395 views2 min read

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option

Silo PharmaSeptember 30, 2022

ENGLEWOOD CLIFFS, NJ, Sept. 30, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the un... Read More...

879 views3 min read

Numinus to Participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022

Numinus WellnessSeptember 29, 2022

VANCOUVER, BC, Sept. 29, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) ( OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in ... Read More...

122 views4 min read

Ketamine Wellness Centers (KWC) Expands Insurance Coverage with Medicare for Ketamine Therapy Patients

Delic HoldingsSeptember 29, 2022

KWC will serve more patients than any other ketamine therapy provider with addition of Medicare, cements status as nation's largest ketamine clinic network in the U.S.  Medicare coverage will be available for patients in eight cities with more to come GILBERT, Ariz., Sept. 29, 2022 - Ketamine Wellness Centers (KWC), the largest ketamine t... Read More...

Financials1283 views4 min read

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

PharmaTher HoldingsSeptember 29, 2022

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion products, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders Seeking FDA approval for the Company’s ketamine injection and infusion products ... Read More...

473 views5 min read

Psyence Group Completes Export of Psilocybin Mushrooms to Portugal

Psyence GroupSeptember 29, 2022

TORONTO, Sept. 29, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce that it has successfully exported medical grade psilocybin mushrooms to Psilo Pharma Inc. (“Psilo Pharma”), from its federally licensed ISO22000 certified production facility in Southern Africa, through its research... Read More...

1380 views6 min read

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi HealthSeptember 22, 2022

Optimi Health Corp.Optimi aiming to become the first vertically integrated psychedelics firm to formulate and trial MDMA for healthy subjectsVANCOUVER, British Columbia, Sept. 22, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and... Read More...

1139 views4 min read

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

Psyence GroupSeptember 22, 2022

TORONTO, Sept. 22, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in Canada. Psilo Scientific, a wholly owned subsidiary of Filament Health Corp., is an exclusively natural psychedelic drug discovery and extraction company. Psyence ... Read More...

849 views4 min read

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Psyence GroupSeptember 19, 2022

TORONTO, Sept. 19, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is delighted to announce that it has received approval for its Phase IIa clinical trial from the Medicines and Healthcare pr... Read More...

1339 views5 min read

Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Numinus WellnessSeptember 19, 2022

Treatment will be offered at the Neurology Centre of Toronto in Forest Hill VANCOUVER, BC, Sept. 19, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) ( OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its Toronto clinic, the Neurol... Read More...

560 views4 min read

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

Revive TherapeuticsSeptember 16, 2022

TORONTO, Sept. 16, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s Phase I/II clinical study of oral psiloc... Read More...

1140 views4 min read

Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive TherapeuticsSeptember 14, 2022

Revive Therapeutics Ltd.TORONTO, Sept. 14, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has filed an amended protocol to the U.S.... Read More...

M & A714 views6 min read

Numinus provides update on acquisition integration and announces new client financing options

Numinus WellnessSeptember 13, 2022

US clinics acquired from Novamind demonstrating continued growth Physical rebranding of clinics is underway Announcing new client financing options in Canada VANCOUVER, BC, Sept. 13, 2022 - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) ( OTCQX: NUMIF) is pleased to provide an update on the integration of the Novamind acqu... Read More...